[Form 4] HOOKIPA Pharma Inc. Insider Trading Activity

Rhea-AI Filing Summary

Malte Peters, CEO and director of HOOKIPA Pharma Inc. (HOOK), reported an insider sale. On 08/19/2025 he disposed of 25,172 shares of the issuer's common stock for a weighted average price of $0.8217 per share. Following the transactions he beneficially owns 54,347 shares. The Form 4 notes the sale occurred in multiple transactions at prices ranging from $0.8205 to $0.8225 and offers to provide a breakdown of the number of shares sold at each price on request. The filing is signed by Malte Peters on 10/09/2025.

Positive

• Full disclosure of sale details including weighted-average price and price range
• Reporting by CEO and director was timely and includes offer to provide per-trade breakdown

Negative

• Insider sold 25,172 shares, reducing reported beneficial holdings to 54,347 shares
• Sale may be viewed as a reduction in insider ownership levels (transaction dated 08/19/2025)

Insights

Corporate Governance Analyst

TL;DR: A CEO/director executed an open-market sale and fully reported it on Form 4.

The filing shows Malte Peters as both Chief Executive Officer and director, reporting a sale of 25,172 shares on 08/19/2025 and a post-transaction beneficial ownership of 54,347 shares. The report follows standard Section 16 disclosure practices by listing transaction codes and a weighted-average price.

This disclosure reduces the reported insider stake and is transparent about price ranges; investors can verify timing and prices from market records if needed within regulatory windows over the next few trading sessions.

Insider Transactions Analyst

TL;DR: Sale details are explicit, including weighted-average price and price range.

The Form 4 discloses a weighted average sale price of $0.8217 and notes individual trade prices ranged from $0.8205 to $0.8225. The reporter offers to provide the per-trade breakdown upon request, which supports transaction traceability.

Because the filing lists exact share counts and dates, market participants can match these to exchange records for the 08/19/2025 trades; monitor any subsequent Form 4s for changes in beneficial ownership.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Peters Malte

(Last) (First) (Middle)

C/O HOOKIPA PHARMA INC.

350 FIFTH AVENUE, 72ND FLOOR, SUITE 7240

(Street)

NEW YORK NY 10118

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
HOOKIPA Pharma Inc. [ HOOK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/19/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/19/2025		S		25,172	D	$0.8217(1)	54,347	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.8205 to $0.8225 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

	Malte Peters	10/09/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many shares did Malte Peters sell according to the Form 4 for HOOK?

The filing reports a sale of 25,172 shares on 08/19/2025.

At what price were the shares sold in the HOOK Form 4?

The weighted average sale price reported is $0.8217, with individual trades ranging from $0.8205 to $0.8225.

How many HOOK shares does Malte Peters beneficially own after the reported sale?

After the reported transactions he beneficially owns 54,347 shares.

What positions does the reporting person hold at HOOK?

The reporting person is listed as both a Director and the Chief Executive Officer.

When was the Form 4 signed by Malte Peters?

The Form 4 is signed by Malte Peters on 10/09/2025.